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Abstract
Background: Numerous factors that contribute to malignant glioma invasion have been identified, but the upstream 
genes coordinating this process are poorly known.
Methods: To identify genes controlling glioma invasion, we used genome-wide mRNA expression profiles of primary 
human glioblastomas to develop an expression-based rank ordering of 30 transcription factors that have previously 
been implicated in the regulation of invasion and metastasis in cancer.
Results: Using this approach, we identified the oncogenic transcriptional repressor, SNAI2/Slug, among the upper 
tenth percentile of invasion-related transcription factors overexpressed in glioblastomas. SNAI2 mRNA expression 
correlated with histologic grade and invasive phenotype in primary human glioma specimens, and was induced by 
EGF receptor activation in human glioblastoma cells. Overexpression of SNAI2/Slug increased glioblastoma cell 
proliferation and invasion in vitro and promoted angiogenesis and glioblastoma growth in vivo. Importantly, 
knockdown of endogenous SNAI2/Slug in glioblastoma cells decreased invasion and increased survival in a mouse 
intracranial human glioblastoma transplantation model.
Conclusion: This genome-scale approach has thus identified SNAI2/Slug as a regulator of growth and invasion in 
human gliomas.
Background
Malignant gliomas characteristically invade the sur-
rounding brain, making them incurable by surgery alone.
Glioma cell invasion depends upon multiple factors,
including extra-cellular matrix (ECM) molecules, growth
factors, and the activity of intracellular pathways regulat-
ing cell motility [1]. However, the upstream mechanisms
that control glioma invasion are poorly known.
Recent studies have revealed the existence of several
transcription factors that control genetic programs pro-
moting metastasis and invasion in human cancer [2].
Among these is Slug, an oncogenic transcriptional
repressor that acts as a master regulator of cell migration
in many tissues [3]. Slug is the product of the SNAI2 gene
and is overexpressed in numerous cancers, including leu-
kemia [4,5], esophageal cancer [6], lung cancer [7], breast
cancer [8,9], ovarian cancer [8,10], prostate cancer [11],
and colorectal cancer [12]. Transgenic mice overexpress-
ing Slug develop leukemias and mesenchymal tumors,
demonstrating an oncogenic role for this protein [13]. In
addition to its effects on migration and tumorigenesis,
Slug inhibits p53-dependent apoptosis by antagonizing
the trans-activation of PUMA by p53 [14].
Despite the evidence that Slug is involved in several
types of peripheral cancers, a role for Slug in human ner-
vous system tumors has not yet been identified. We show
here that SNAI2/Slug is overexpressed in a subpopulation
of glioblastomas in an EGF-dependent manner, and
SNAI2/Slug mRNA expression correlates with increasing
tumor grade and invasive phenotype in human gliomas.
We also demonstrate that SNAI2/Slug promotes invasion
and growth in human glioblastomas.
Methods
Cell lines and tumor samples of astrocytoma and 
glioblastoma multiforme
All studies were performed after written informed con-
sent was obtained under the auspices of a human subjects
institutional review board (IRB) protocol approved by the
Partners Human Research Committee. Primary frozen
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tissue from 78 human glioma specimens (including 15
low grade astrocytomas, 15 low grade oligodendro-
gliomas, 10 low grade gangliogliomas, 7 anaplastic astro-
cytomas and 31 glioblastomas (GBMs) were obtained
from the Brain Tumor Tissue Bank in the Department of
Neurosurgery at Brigham and Women's Hospital. Four
human glioblastoma cell lines (U87, U251, U343, and
T98) were obtained from the American Tissue Type Cul-
ture Collection. The D566 human glioblastoma cell line
was a gift from D. Bigner, Duke University. All cell lines
were cultured in DMEM (Invitrogen, Carlsbad, CA) sup-
plemented with 10% FBS, and were maintained in a 5%
CO2 incubator at 37°C.
mRNA expression profiling
Total RNA was isolated from 20 fresh frozen human
glioma samples and from 7 non-tumor brain samples. In
some experiments, RNA was isolated from U87 human
glioblastoma cells after transduction with a SNAI2/Slug
lentivirus or a control virus. The mRNA was reverse-
transcribed to generate cDNA, which was then biotiny-
lated and hybridized to Affymetrix HG-U133A expres-
sion arrays prior to scanning for quantitation. For data
from primary glioma specimens, expression heatmaps
were constructed using expression data from the non-
tumor brain specimens as a reference. Statistical compar-
isons between histologic subgroups were performed
using the t-test.
Taqman Real-time PCR
Total RNA was extracted from cell lines with TRIzol
(Invitrogen, Carlsbad, CA), according to the manufac-
turer's protocol. Randomly primed cDNA was prepared
using 1 μg of total RNA from each sample and the AMV
1st Strand cDNA Synthesis Kit (Roche Applied Science,
Indianapolis, IN). Six ng of each cDNA were then used
for real-time PCR analysis in a final reaction volume of 20
μl. Probes for β-actin (Hs99999903_m1) and human
SNAI2/Slug (Hs00161904_m1) were purchased from
Applied Biosystems (Foster City, CA). Samples were ana-
lyzed in triplicate using the ABI 7300 software system
(Applied Biosystems, Foster City, CA) with DDCt quanti-
fication. Statistical analysis was performed using the t-
test.
Lentivirus production and establishment of stable glioma 
lines
The full length human SNAI2 gene was cloned by R T -
PCR from U87 cells using the forward primer 5'- CAC
CAT GCC GCG CTC CTT CCT GGT C-3' and the
reverse primer 5'-TCA GTG TAC ACA GCA GCC AGA-
3', and was subsequently transferred into the pLenti6-
IRES-EGFP vector. The correct SNAI2  sequence was
confirmed by direct DNA sequencing. A lentiviral
shRNA vector for Slug and an appropriate empty control
vector were purchased from Open Biosystems
(TRCN0000015389, Huntsville, AL). The lentiviral vec-
tors were packaged in 293FT cells using the ViraPower
Lentiviral Expression System (Invitrogen, Carlsbad, CA)
according to the manufacturer's protocol.
Human U251 and U87 glioblastoma cells were trans-
duced with the appropriate lentiviruses, and stable cell
lines (U251-IRES-GFP and U251-Slug-IRES-GFP) were
selected using 8 μg/ml blasticidin. U87-pLKO.1 and U87-
shSlug stable cell lines were selected using puromycin.
Growth and proliferation assays
To measure cell growth, 1 × 103 glioma cells were plated
into 96 well culture plates in triplicate, and cell growth
was determined from day 0 to day 6 using a tetrazolium
salt-based colorimetric assay (Cell Counting Kit-8,
Dojindo Molecular Technologies, Gaithersburg, MD)
according to the manufacturer's protocol.
To measure cell proliferation, 1 × 103 human glioma
cells were plated into 96 well culture plates in triplicate
and cultured for 6 hours. The cells were then incubated in
BrdU overnight at 37°C. BrdU incorporation into DNA
was quantitated by ELISA assay (Roche Applied Science,
Indianapolis, IN) according to the manufacturer's proto-
col.
Western blots
Total protein was extracted using RIPA buffer supple-
mented with proteinase inhibitors. Protein extracts were
then separated by gel electrophoresis using 4-20% SDS-
PAGE - Tris-HCl gels (Bio-Rad, Hercules, CA). The pro-
tein was transferred to nitrocellulose membranes and
detected using a specific anti-Slug antibody (G-18, Santa
Cruz Biotechnologies, Santa Cruz, CA) at a 1:1000 dilu-
tion. After washing and incubation in the appropriate
secondary antibody, immunoreactive bands were visual-
ized using the enhanced chemiluminescence system.
Immunohistochemistry
Animals containing subcutaneous tumors were anesthe-
tized, and the subcutaneous tumors were then harvested,
fixed with 4% paraformaldehyde at pH 7.4, immersed in
30% sucrose, embedded in OCT and cryostat-sectioned
at 6 μm at -20°C. Hematoxylin and eosin (H&E) staining
was performed, and immunohistochemistry was per-
formed using the Vectastain Elite ABC kit (Vector Labo-
ratories, Burlingame, CA). A specific anti-CD31 primary
antibody (1:100; BD Biosciences PharMingen) was used
to visualize blood vessels.
In vitro cell migration and invasion assays
Cell migration was measured using the in vitro scratch
wound healing assay [15] and transwell assay [16]. For the
wound healing assay, U251-IRES-GFP and U251-Slug-Yang et al. BMC Cancer 2010, 10:301
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IRES-GFP cells were cultured at 37°C in DMEM supple-
mented with 10% FBS until confluence was achieved. A
cell-free area was then created by scratching the mono-
layer with a pipette tip, and the culture was photographed
at time 0 and after 24 hours. The distance migrated from
the edge of the scratch was measured using an automated
imaging software program (SPOT, Diagnostic Instru-
ments, Sterling Heights, MI).
For the transwell assay, 10 mm tissue culture inserts
with polycarbonate membranes (8 μm pore, Nalge Nunc
International, Rochester, NY) were used according to the
manufacturer's protocol. Briefly, 1 × 105 U251-IRES-GFP
or U251-Slug-IRES-GFP cells were suspended in DMEM
supplemented with 1% FBS and plated into the 10 mm
t i s s u e  c u l t u r e  i n s e r t s .  D M E M  s u p p l e m e n t e d  w i t h  1 0 %
FBS was used in the lower chamber as a chemoattractant,
and the cells were allowed to migrate overnight. The cells
that failed to migrate (located on the upper surface of the
membrane) were removed using a cotton swab. The
membranes were then stained with the 3 Step Stain Set
(eosin-Y, azure A and methylene blue, Richard-Allen Sci-
entific, Kalamazoo, MI), dried and mounted using
Cytoseal 60. The cell number was determined by calculat-
ing the mean number of cells from five separate 40 ×
fields. The same protocol was used for the migration of
U87-pLKO.1 and U87-shSlug cells, except that the migra-
tion time was decreased to 5 hours.
Invasion by glioblastoma cells in vitro was measured
using the Matrigel invasion assay [17]. The BD BioCoat
Matrigel invasion chamber (8 μm pore, BD Biosciences,
San Jose, CA) was used according to the manufacturer's
protocol. Briefly, 1 × 105 U251-IRES-GFP and U251-Slug-
IRES-GFP cells were suspended in DMEM with 1% FBS
and plated onto 10 mm tissue culture inserts. DMEM
containing 10% FBS was placed into the lower chamber,
and the cells were allowed to invade through the matrix
overnight. All incubations were conducted at 37°C with
5% CO2. The cells that failed to migrate through the
membrane were removed with a cotton swab, and the
membranes were stained with the 3 Step Stain Set for
blood smear (Richard-Allen Scientific, Kalamazoo, MI).
The cell number was determined by taking the average
from five separate 40 × fields. Statistical significance was
determined using the t-test.
Intracranial and subcutaneous tumor growth and survival 
assays
All animal experimental procedures were carried out in
the animal facility at Brigham and Women's Hospital
under the auspices of an approved protocol and in accor-
dance with federal, local and institutional guidelines. For
the subcutaneous tumor growth assay, approximately 5 ×
105 U251-IRES-GFP or U251-Slug-IRES-GFP cells were
subcutaneously injected into the flanks of 5-week-old
nude mice. The tumor volumes were measured each
week beginning with the second week after injection, and
the tumors were allowed to grow for an additional 6
weeks. At the termination of the study, the mice were
euthanized and the tumors were surgically removed and
processed for histochemistry. A total of 4 mice were stud-
ied in each group. Tumor volume was calculated from the
length (a) and width (b) using the formula V = 4/3π(ab2/
2) [18]. Statistical significance was determined using the
t-test.
For the intracranial orthotopic human glioma model,
approximately 5 × 104 U87-pLKO.1 or U87-shSlug glio-
blastoma cells were injected intracranially into the frontal
cortex of 5-week-old male nude mice. Six mice in the
control group and 5 mice in the U87-shSlug group
received intracranial human glioblastoma cell trans-
plants. The animals were then followed until they showed
signs of neurologic dysfunction or distress, at which time
they were sacrificed. Kaplan-Meier survival analysis was
then performed, and statistical significance was deter-
mined using the Logrank test.
Results
SNAI2/Slug expression correlates with grade and invasive 
phenotype in gliomas
To identify upstream determinants of invasiveness in
human gliomas, we performed a screen of 30 transcrip-
tion factors implicated in the regulation of invasion and
metastasis in other cancers. These factors were selected
after a search of the Pubmed database using the search
terms transcription factor and metastasis, invasion or
migration. Expression of the mRNA for these transcrip-
tion factors was then examined in a panel of 20 human
glioblastomas using mRNA microarray analysis, and the
transcription factors were rank ordered based upon their
degree of overexpression when compared to non-tumor
brain. Using this approach, we identified HIF1A, STAT3
and SNAI2 (Slug) as the three most overexpressed migra-
tion-related transcription factors in human glioblastomas
when compared to non-tumor brain (Figure 1A). Previ-
ous reports have indicated key roles for HIF1A  and
STAT3  in glioblastoma aggressiveness [17,19,20], con-
firming the validity of this rank-order approach for iden-
tifying upstream transcription factors regulating the
invasive phenotype of human gliomas. However, a role
for SNAI2/Slug in human gliomas has not been reported
previously. The frequency and extent of SNAI2/Slug
mRNA overexpression exceeded that of 26 of the 30 inva-
sion/migration-related transcription factors examined,
several of which have been implicated specifically in
glioma invasion. Among these were AP1, NFKB1, and
TWIST1 [21,22].
Different histologic subtypes of glioma show a differen-
tial tendency to invade the surrounding brain. AlthoughYang et al. BMC Cancer 2010, 10:301
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gangliogliomas can infiltrate the surrounding brain
parenchyma, they are often relatively well circumscribed,
so that they can sometimes be cured by surgical resection
[23]. In contrast, low grade diffuse fibrillary astrocytomas
are generally more invasive than gangliogliomas, while
low grade oligodendrogliomas display an intermediate
invasive phenotype. In addition, glioma invasion corre-
lates with tumor grade, with malignant gliomas (e.g. glio-
blastomas) being more invasive than low grade gliomas.
To determine whether SNAI2/Slug expression correlates
with these parameters, we examined SNAI2/Slug mRNA
expression in 78 human gliomas of different histologic
subtypes and grades (Figure 1B). Mean SNAI2/Slug
mRNA expression was low in non-tumor brain (112 ± 42)
and in gangliogliomas (119 ± 52), which have low invasive
potential. Mean SNAI2/Slug mRNA levels were higher in
low grade oligodendrogliomas (143 ± 78) and in low
grade diffuse fibrillary astrocytomas (158 ± 120). Impor-
tantly,  SNAI2/Slug mRNA expression was significantly
higher in glioblastomas than in low grade diffuse astrocy-
tomas or in non-tumor brain (P < 0.006, t-test). We con-
firmed overexpression of SNAI2/Slug mRNA by real-time
PCR in 9 low grade astrocytomas (LGA) and 17 glioblas-
tomas (GBMs). Elevated expression of SNAI2/Slug
Figure 1 SNAI2/Slug mRNA is overexpressed in human gliomas and correlates with histologic grade and invasive phenotype. A) mRNA ex-
pression heatmaps for 30 migration/invasion-related transcription factors. Data shown was obtained from 20 primary human glioblastoma specimens 
(10 upper panel, 10 lower panel). Changes in glioblastoma gene expression are shown relative to mean expression values obtained from 7 non-tumor 
brain specimens. Heatmaps are ordered according to their degree of overexpression relative to non-tumor brain. B) mRNA microarray data for SNAI2 
expression in 79 human glioma specimens. Data shown was obtained using 5 non-tumor brain specimens (NTB), 10 supratentorial ganglioglioma 
(GG) specimens, 15 low grade oligodendroglioma specimens (LGO), 15 low grade astrocytoma specimens (LGA), 7 anaplastic astrocytoma (AA) spec-
imens and 32 glioblastoma (GBM) specimens. Intensity data is plotted on the y axis. SNAI2/Slug mRNA expression was elevated in glioblastomas com-
pared to low grade astrocytomas (P < 0.006, t-test). C) Real-time PCR analysis of SNAI2/Slug mRNA expression in non-tumor brain (NB), low grade 
astrocytoma (LGA) and glioblastoma (GBM) specimens. D) Relative quantification of SNAI2/Slug mRNA expression using Real-time PCR in several hu-
man glioblastoma cell lines (U343, U251, T98, D566 and U87). Data from non-tumor brain specimens is shown for comparison.Yang et al. BMC Cancer 2010, 10:301
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mRNA when compared to non-tumor brain (NB) was
observed in 2 of 9 (22%) low grade astrocytomas and 6 of
17 (35%) glioblastomas (Figure 1C).
We also examined SNAI2/Slug mRNA expression in 5
human glioma cell lines. SNAI2/Slug mRNA expression
was increased more than 9 fold in U87, D566 and T98
human glioma cell lines when compared to non-tumor
brain tissues, while the U251 and U343 glioma cell lines
showed  SNAI2/Slug expression levels similar to those
observed in non-tumor brain (Figure 1D).
We next used Western blot analysis to determine Slug
protein expression in primary human glioblastoma speci-
mens. Slug protein was undetectable in 5 human non-
tumor brain specimens. In contrast, Slug protein expres-
sion was elevated in 5 of 13 (38%) human glioblastoma
specimens examined (Figure 2A). Slug protein expression
correlated closely with SNAI2/Slug mRNA levels (Figure
2A).
In epithelial cells, SNAI2/Slug expression can be
increased by EGF receptor activation[24]. We observed a
significant increase in SNAI2 mRNA and protein in U251
glioblastoma cells after EGF exposure (Figure 2B).
Although Slug is also a downstream effector of the SCF/
c-kit pathway[25], we failed to detect an increase in
SNAI2/Slug mRNA after SCF exposure in U251 glioblas-
toma cells (data not shown). Taken together, these data
indicate that SNAI2/Slug is overexpressed in a subpopu-
lation of human gliomas, and its expression correlates
with invasive phenotype and tumor grade.
SNAI2/Slug promotes growth and proliferation in 
glioblastoma
To determine the consequences of SNAI2/Slug overex-
pression in human gliomas, we first generated an IRES-
EGFP lentivirus containing the human SNAI2  gene. A
lentivirus containing an empty IRES-EGFP vector was
prepared as a control. Human U251 glioblastoma cells
were then transduced with these lentiviruses and stable
cell lines were produced (Figure 3A). Overexpression of
Slug protein in U251 glioblastoma cells transduced with
the SNAI2/Slug lentivirus was confirmed by Western blot
(Figure 3B). In vitro growth assays indicated that glioblas-
toma cells overexpressing SNAI2/Slug grew significantly
Figure 2 Slug is overexpressed in glioblastoma and induced by EGF. A) upper panel Western blot analysis of protein isolates derived from 6 hu-
man glioblastoma (GBM) and 3 human non-tumor brain (NB) specimens. Blots were stained using a specific anti-Slug antibody. β-actin was used as 
an internal reference for normalization. The Western blot analysis showed low or absent Slug protein expression in all three non-tumor brain speci-
mens and increased Slug expression in five of six GBM specimens. lower panel mRNA was isolated from the same tumor specimens used in the upper 
panel and quantitative Real-time PCR for SNAI2 mRNA was performed as described. Data shown are the mean of three replicates. B) upper panel Slug 
protein was isolated from U251 human GBM cells after exposure to EGF (50 or 100 ng/ml) for 4 hours and assayed by Western blot. β-actin was used 
as an internal reference for normalization. lower panel Real-time PCR analysis of SNAI2 mRNA from the same samples displayed in the upper panel. Data 
shown are mean ± SEM of three replicates.Yang et al. BMC Cancer 2010, 10:301
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faster than control cells (Figure 3C, P < 0.03, t-test). To
investigate this phenomenon further, we examined prolif-
eration by measuring bromodeoxyuridine (BrdU) incor-
poration into DNA. Human U251 glioblastoma cells
overexpressing Slug displayed a higher rate of DNA syn-
thesis than did control cells (Figure 3D, P < 0.00001, t-
test).
Slug increases migration and invasion in human gliomas
Our analysis of SNAI2/Slug expression in primary glioma
specimens suggested a relationship between SNAI2/Slug
and invasive phenotype. To determine the basis for this
relationship, we first performed an in vitro scratch wound
healing assay using human U251 glioblastoma cells. Glio-
blastoma cells overexpressing SNAI2/Slug migrated
approximately 62 μm from the edges and covered 63% of
the scratch defect (Figure 4A), while control cells express-
ing the empty IRES-EGFP vector migrated only 39 μm
from the edges and covered less than 39% of the scratch
defect (Figure 4A, P < 0.00001, t-test).
We also examined the effect of SNAI2/Slug on chemot-
axis in glioblastoma cells using a transwell migration
assay and 10% serum as a chemoattractant (Figure 4B).
Significantly more U251 glioblastoma cells overexpress-
ing  SNAI2/Slug migrated through the membrane than
did control cells (184 +/- 15 cells/hpf versus 83 +/- 9 cells/
hpf, P < 0.00001, t-test).
Finally, we utilized a three dimensional Matrigel inva-
sion assay to determine the effect of SNAI2/Slug expres-
s i o n  o n  g l i o m a  i n v a s i o n  ( F i g u r e  4 C ) .  W e  f o u n d  t h a t
significantly more U251 glioblastoma cells overexpress-
ing SNAI2/Slug passed through the matrix than did con-
Figure 3 SNAI2/Slug overexpression increases glioblastoma growth and proliferation. A) Phase and fluorescence micrographs showing human 
U251 glioblastoma cells transduced with a Slug-IRES-EGFP lentivirus. B) Western blot analysis demonstrating increased Slug protein expression in 
U251 glioblastoma cells transduced with the Slug-IRES-GFP lentivirus. C) Colorimetric growth assay demonstrating growth curves for human U251 
glioblastoma cells overexpressing a vector containing SNAI2/Slug (solid line) or an empty control vector (dashed line). Data shown are mean ± SEM. 
Slug-expressing glioblastoma cells grew at a significantly faster rate than control cells (P < 0.03, t-test). D) BrdU incorporation into DNA for human U251 
glioblastoma cells overexpressing an SNAI2/Slug vector or an empty control vector. Data shown are mean ± SEM. SNAI2/Slug-expressing glioblastoma 
cells synthesized new DNA at a significantly faster rate than control cells (asterisk indicates P < 0.00001, t-test).Yang et al. BMC Cancer 2010, 10:301
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trol cells (83 +/- 10 cells/hpf versus 59 +/- 7 cells/hpf, P <
0.001, t-test). Taken together, these results indicate that
enforced overexpression of SNAI2/Slug increases migra-
tion and invasion in human glioblastoma cells.
In order to determine the role of endogenous SNAI2/
Slug in glioma invasion, we examined whether knock-
down of SNAI2/Slug expression in glioblastoma cells with
high endogenous expression of SNAI2/Slug could inhibit
migration and invasion. The U87 human glioblastoma
cell line was chosen for these studies because it displayed
a high endogenous level of SNAI2/Slug mRNA and pro-
tein expression (cf. Figure 1D). We first generated lentivi-
ruses containing either a control vector or an shRNA
vector directed against SNAI2/Slug. Human U87 glio-
Figure 4 Overexpression of SNAI2/Slug increases glioblastoma migration and invasion. A) Scratch wound healing assay for human U251 glio-
blastoma cells overexpressing a control vector or a SNAI2/Slug vector. Cells were photographed at 0 hours and 24 hours after scratch application. The 
dotted lines indicate the original edges of the scratch defect. B) Transwell migration assay for human U251 glioblastoma cells overexpressing SNAI2/
Slug or a control vector. 10% serum was used as a chemoattractant. The cells that migrated through the membrane were stained and counted under 
direct microscopy. Slug-expressing glioblastoma cells migrated faster than the control cells (asterisk indicates P < 0.00001, t-test). C) 3-dimensional 
Matrigel assay for human U251 glioblastoma cells overexpressing a SNAI2/Slug vector or a control vector. After 24 hours, cells that invaded through 
the matrix were fixed, stained with H&E and counted under direct microscopy. Data shown are mean ± SEM. Glioblastoma cells overexpressing Slug 
showed greater invasiveness than did control cells (asterisk indicates P < 0.001, t-test).Yang et al. BMC Cancer 2010, 10:301
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blastoma cells were then transduced with these lentivi-
ruses to generate stable cell lines. Taqman Real-time PCR
indicated that the SNAI2/Slug shRNA suppressed SNAI2/
S lug  m RNA e x p r ess io n by m or e  t ha n 60% whe n c om -
pared to control cells (Figure 5A). ShRNA-mediated
knockdown of Slug protein was confirmed by Western
blot (Figure 5A).
As shown in Figure 5B, U87 glioblastoma cells overex-
pressing SNAI2/Slug shRNA displayed decreased migra-
tion when compared to control cells (39 +/- 9 cells/hpf
versus 72 +/- 7 cells/hpf, P < 0.0002, t-test), indicating a
role for endogenous SNAI2/Slug expression in glioblas-
toma cell migration. To determine the effect of endoge-
nous SNAI2/Slug on glioblastoma cell invasion, we again
utilized the Matrigel invasion assay (Figure 5C). After
SNAI2/Slug knockdown, significantly fewer U87 glioblas-
toma cells invaded through the matrix when compared to
cells expressing an empty control vector (24 +/- 2 cells/
Figure 5 Knockdown of endogenous SNAI2/Slug decreases glioblastoma migration and invasion. A) Human U87 glioblastoma cells were 
transduced to over express an shRNA directed against SNAI2/Slug (shSlug) or a control vector. Total RNA was then collected and analyzed for SNAI2/
Slug mRNA expression by Taqman Real-time PCR. shSlug decreased SNAI2/Slug mRNA expression by approximately 60%. shRNA-mediated knock-
down of Slug protein was confirmed by Western blot (right panel). B) Transwell migration assay for human U87 glioblastoma cells overexpressing an 
shRNA directed against SNAI2/Slug or a control vector. 10% serum was used as a chemoattractant. The cells that migrated through the membrane 
were stained with H&E and counted under direct microscopy. shSlug-expressing glioblastoma cells migrated slower than the control cells (asterisk 
indicates P < 0.0002, t-test). C) 3-dimensional Matrigel assay for human U87 glioblastoma cells overexpressing an shRNA directed against Slug or a 
control vector. 24 hours after plating, cells that invaded through the matrix were stained and counted under direct microscopy. Data shown are mean 
± SEM. Glioblastoma cells overexpressing shSlug showed less invasion than control cells (asterisk indicates P < 0.0001, t-test).Yang et al. BMC Cancer 2010, 10:301
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hpf vs. 47 +/- 5 cells/hpf, P  < 0.0001, t-test). Taken
together, these findings indicate that endogenous SNAI2/
Slug promotes the migration and invasiveness of human
glioblastoma cells.
SNAI2/Slug regulates glioma growth and angiogenesis in 
vivo
The effects of Slug on glioma cell growth and invasion in
vitro suggested that this transcription factor might pro-
mote glioma aggressiveness in vivo. We investigated this
possibility using both subcutaneous and intracranial
mouse transplantation models. First, we injected U251
glioblastoma cells transduced with a SNAI2/Slug lentivi-
rus or a control lentivirus subcutaneously into the flanks
of nude mice. Tumor size was then measured weekly for a
period of 8 weeks. On average, human glioblastoma cells
overexpressing  SNAI2/Slug formed larger tumors than
did control cells (Figure 6A, left panel). The average
weight of tumors in which SNAI2/Slug was overexpressed
was 101 +/- 43 mg, while that of control tumors was 38 +/
- 10 mg. Growth curves indicated that glial tumors over-
expressing SNAI2/Slug grew at a significantly faster rate
in vivo than did control tumors (Figure 6A, P < 0.007 at 4
weeks, t-test).
The harvested subcutaneous tumors were also pro-
cessed for histologic analysis. Tumor cells in which
SNAI2/Slug was overexpressed displayed a more spindle-
like morphology when compared to control cells (Figure
6B). Staining of tumor vasculature using a CD31 antibody
(Figure 6C) revealed increased vascular proliferation in
tumors in which SNAI2/Slug was overexpressed when
compared to control tumors (19 +/- 4 CD31 positive ves-
sels/hpf versus 8 +/- 1 CD31 positive vessels/hpf, P  <
0.002, t-test). Thus, increased SNAI2/Slug expression
promotes growth and angiogenesis in human gliomas, as
has been reported for lung carcinoma [7].
Studies in other tissues indicate that SNAI2/Slug can
increase the expression of angiogenic factors such as
VEGF and basement membrane proteins[26], and can
promote growth by repressing p53-mediated transactiva-
tion of the BBC3/PUMA gene[14]. We therefore exam-
ined whether SNAI2/Slug might have similar effects on
gene expression in human glioma cells using mRNA
microarray analysis. As observed in other cell types, over-
expression of SNAI2/Slug in U251 glioblastoma cells
decreased  BBC3/PUMA mRNA expression and
increased expression of angiogenic factors such as VEGF,
IL8 and several extracellular matrix proteins by more
than 1.5 fold (Figure 6D). To confirm that Slug increases
IL8 expression, we quantified IL8 mRNA expression by
Real-time PCR using U251-Slug-IRES-GFP and U87-sh-
Slug glioblastoma cells. Overexpression of Slug increased
IL8 mRNA expression approximately 10 fold, and knock-
down of Slug in U87 cells significantly suppressed IL8
mRNA expression (Figure 6D).
Additional evidence for a correlation between SNAI2/
Slug and VEGF was obtained using mRNA microarray
data from primary glioblastoma samples. A plot of VEGF
mRNA expression versus SNAI2/Slug mRNA expression
in 20 human glioblastoma specimens revealed a weak but
positive correlation (Figure 6E). This relationship was pri-
marily due to the finding of low VEGF mRNA levels at
very low levels of SNAI2 mRNA expression. Importantly,
this same pattern was observed using an independent,
publicly-available mRNA expression data set derived
from approximately 50 human glioblastomas [27]. These
findings suggest that, in addition to its effects on prolifer-
ation and invasion, SNAI2/Slug promotes angiogenesis in
human glioblastomas.
To investigate whether knockdown of SNAI2/Slug
could improve survival in a mouse intracranial human
glioma transplantation model, we transplanted human
U87 glioblastoma cells overexpressing a control vector or
an shRNA vector directed against SNAI2/Slug into the
brains of 5-week-old nude mice and followed the animals
until they developed signs of distress due to glioblastoma
growth. All mice with control U87 glioblastoma cell
transplants died within 20 days, while mice transplanted
with U87 glioblastoma cells overexpressing SNAI2/Slug
shRNA survived as long as 42 days (Figure 6F). Kaplan-
Meier analysis indicated that knockdown of endogenous
SNAI2/Slug significantly prolonged survival (P < 0.0012,
Logrank Test). Taken together, these data indicate that
endogenous SNAI2/Slug promotes growth, invasion and
aggressiveness in human glioblastomas.
Discussion
Migration and invasion in cancer is a complex process
requiring the coordinated action of numerous proteins
and intracellular pathways. Evidence suggests that spe-
cific transcription factors coordinately regulate genetic
programs promoting invasion and metastasis in a tumor-
specific manner [2]. A characteristic feature of human
malignant gliomas is their ability to diffusely invade nor-
mal brain tissues. Our findings demonstrate that aberrant
expression of SNAI2/Slug, a master transcriptional regu-
lator of invasion, contributes to this invasive behavior in
gliomas. We observed that SNAI2/Slug expression corre-
lates with histologic grade and tumor subtype, such that
the most invasive gliomas (glioblastomas) displayed the
highest levels of SNAI2/Slug expression. The degree of
SNAI2/Slug overexpression in primary human glioblas-
toma specimens and its effects on growth and invasion by
glioma cells are comparable to those of two other tran-
scription factors involved in gliomagenesis, i.e. HIF1A
and STAT3. Both overexpression and knockdown studies
indicate that SNAI2/Slug increases glioblastoma growthYang et al. BMC Cancer 2010, 10:301
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and invasion in vitro. Moreover, inhibition of endogenous
SNAI2/Slug expression improves survival in a mouse
intracranial human glioblastoma transplantation model.
SNAI2/Slug acts as an oncogene in hematopoietic and
other peripheral tissues [13]. SNAI2/Slug appears to have
a function similar to that of the TWIST1 transcription
factor, in that both can promote the epithelial-to-
mensenchymal transition (EMT) in non-neural
cells[9,22]. We observed that SNAI2/Slug overexpressing
glioblastoma cells display a different phenotype and are
more invasive than control glioblastoma cells, suggesting
that they may have adopted more mesenchymal charac-
teristics. Interestingly, a subclass of glioblastoma with
increased mesenchymal differentiation has been
reported[27]. Preliminary analysis in our laboratory indi-
cates that SNAI2  mRNA is indeed upregulated in the
mesenchymal subclass of glioblastomas (unpublished
observations).
We observed that SNAI2/Slug increased the growth of
both U251 and U87 human glioblastoma cells. In this
Figure 6 Slug promotes glioblastoma growth and decreases survival in vivo. A) Human U251 glioblastoma cells transduced with a Slug-IRES-
EGFP lentivirus or a control lentivirus were implanted subcutaneously into the flanks of nude mice. Quantitative data on tumor growth is shown on 
the right. Data shown are mean ± SEM (n = 4). Tumors overexpressing Slug grew at a faster rate than control tumors (P < 0.007 at 4 weeks, t-test). B) 
Histological characteristics of U251 glioblastoma tumors shown in A). Sections are stained with hematoxylin and eosin. Note the spindle morphology 
of the Slug-overexpressing tumors. C) CD31 immunoreactivity in U251 glioblastoma tumors overexpressing Slug or a control vector. Increased CD31 
immunoreactivity was observed in Slug-overexpressing tumors, indicating the presence of increased vascularity (P < 0.002, t-test). D) upper panel 
mRNA microarray data obtained from human U251 glioblastoma cells transduced with either an SNAI2 lentivirus or a control virus. Data are expressed 
as fold change relative to mRNA expression in control cells. lower panels IL8 mRNA expression after Slug overexpression or Slug knockdown was vali-
dated by Real-time PCR in U251-IRES-Slug and U87-ShSlug glioblastma cells, respectively. Data shown are mean ± SEM of three replicates. E) Regres-
sion plot of SNAI2 mRNA versus VEGF mRNA expression. mRNA microarray data was obtained from 20 human glioblastomas. R2 = 0.068. F) U87 human 
glioblastoma cells transduced with a Slug shRNA lentivirus or a control virus were transplanted into the brains of nude mice. Kaplan-Meier survival 
analysis indicated that SNAI2/Slug knockdown significantly improved survival (P < 0.0012, Logrank test).Yang et al. BMC Cancer 2010, 10:301
http://www.biomedcentral.com/1471-2407/10/301
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respect, SNAI2/Slug differs from TWIST1, another tran-
scription factor that promotes glioma invasion, which has
no effect on glioma growth or proliferation[22]. The
effects of SNAI2/Slug on glioma growth are likely related
to the Slug-induced increase in DNA synthesis observed
in glioblastoma cells in the current study. In addition, an
anti-apoptotic effect of SNAI2/Slug has been reported
[14]. In U87 glioblastoma cells, we observed a SNAI2/
Slug-induced downregulation of mRNA expression for
BBC3/PUMA, an effector of p53-induced apoptosis
whose expression is transcriptionally repressed by
SNAI2/Slug [14]. However, the finding that SNAI2/Slug
promoted proliferation and tumor growth in U251 glio-
blastoma cells (which lack functional p53) suggests that
mechanisms other than inhibition of the p53 pathway
contribute to the effects of SNAI2/Slug on glioma growth.
Conclusion
These data reveal a role for the invasion and metastasis-
related transcription factor, SNAI2/Slug in human glio-
blastomas. We find that SNAI2/Slug increases the expres-
sion of IL8, and that SNAI2/Slug expression correlates
positively with the expression of VEGF and other genes
involved in glioma invasion and angiogenesis. In addi-
tion, we show that SNAI2/Slug activates a program of
phenotypic changes in human glioblastoma cells that
includes increased spindle morphology, vasculogenesis,
growth and invasion. Importantly, SNAI2/Slug expres-
sion is increased by EGFR activation and promotes a
mesenchymal phenotype in glioblastoma cells. Taken
together, these findings reveal SNAI2/Slug to be an inte-
gral part of a growth factor-initiated genetic program
promoting human glioblastoma growth and dispersal.
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